Celgene Wants Sun Pharma's Revlimid Generic Blocked
Celgene has asked a New Jersey federal court to stop Sun Pharma from moving forward with its generic version of the blockbuster cancer medication Revlimid until three patents expire....To view the full article, register now.
Already a subscriber? Click here to view full article